Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities.
- DOI
- 10.1016/j.anai.2025.12.017
- Published
- 2026 May
- Container
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.anai.2025.12.017,
title = {Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities.},
author = {Sher ER and Golant A and de Bruin-Weller M and Carrascosa JM and Mehta V and Bieber T and Dawson Z and Atwater AR and Zhong J and Rodriguez Calleja L and Boguniewicz M},
year = {2026},
journal = {Annals of allergy, asthma \& immunology : official publication of the American College of Allergy, Asthma, \& Immunology},
doi = {10.1016/j.anai.2025.12.017},
url = {https://doi.org/10.1016/j.anai.2025.12.017}
}RIS
TY - JOUR TI - Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities. AU - Sher ER AU - Golant A AU - de Bruin-Weller M AU - Carrascosa JM AU - Mehta V AU - Bieber T AU - Dawson Z AU - Atwater AR AU - Zhong J AU - Rodriguez Calleja L AU - Boguniewicz M PY - 2026 JO - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology DO - 10.1016/j.anai.2025.12.017 UR - https://doi.org/10.1016/j.anai.2025.12.017 ER -
APA
ER, S., A, G., M, D. B., JM, C., V, M., T, B., Z, D., AR, A., J, Z., L, R. C., & M, B. (2026). Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. https://doi.org/10.1016/j.anai.2025.12.017
Source records
- pubmed · retrieved 2026-09-26T18:00:32.489Z